Chief Scientific Officer and director (5) · ORAMED PHARMACEUTICALS INC. (ORMP)

Miriam Kidron

A named executive officer of ORAMED PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,166,384

Salary $439,902Stock awards $1,406,033Bonus $271,994

FY2024: $1,534,547

2nd of 3 named executive officers at Oramed Pharmaceuticals by FY2025 total.

3 named officers on file for ORAMED PHARMACEUTICALS, FY2025

Miriam Kidron’s pay file — $29

  • 10 fiscal years of pay, line by line
  • ORMP’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ORAMED PHARMACEUTICALS’s whole pay program stands against its peers

  • ORAMED PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ORMP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed August 3, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Miriam Kidron’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Miriam Kidron compensation by year

ORAMED PHARMACEUTICALS Summary Compensation Table · all 10 fiscal years held
In US dollars, as ORAMED PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Salary$203,378$254,765$273,595$267,386$305,840$319,868$378,569$347,405$408,104$439,902
Bonus$136,583$50,000$46,614$123,149$70,000$86,000$140,231$139,123$155,291$271,994
Stock awards$0$581,932$0$0$0$1,330,451$1,938,580$605,480$951,545$1,406,033
Option awards$0$359,224$253,204$211,128$299,506$584,462$588,947$0$0$0
Non-equity incentive$0$0$0$0$0$0$0$0$0$0
Pension and deferred compensation$0$0$0$0$0$0$0$0$0$0
All other$13,191$12,775$13,643$14,503$13,354$14,193$23,879$17,423$19,607$48,455
Total$353,152$1,258,696$587,056$616,166$688,700$2,334,974$3,070,206$1,109,431$1,534,547$2,166,384

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ORAMED PHARMACEUTICALS INC. DEF 14A filed August 3, 2026, accession 0001213900-26-084609, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ORAMED PHARMACEUTICALS INC. filed document, accession 0001213900-26-084609. Every figure is read from that document and cited to the page and table it appears in. Filed August 3, 2026.

$353K
$1.3M
$587K
$616K
$689K
$2.3M
$3.1M
$1.1M
$1.5M
$2.2M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option18,000—$13.89

Per the Outstanding Equity Awards at Fiscal Year-End table in ORAMED PHARMACEUTICALS INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

10 Form 4 lines since the FY2025 proxy (filed August 3, 2026)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-12Grant or award—242,000—2,149,554
2026-11-12Grant or award—357,000—1,907,554
2026-09-24Disposition to the issuer derivative—100,000—0
2026-09-24Disposition to the issuer derivative—69,999—0
2026-09-24Disposition to the issuer derivative—47,000—0
2026-09-24Disposition to the issuer derivative—100,000—0
2026-09-24Disposition to the issuer derivative—72,000—0
2026-09-24Grant or award—209,291—1,550,554

The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ORAMED PHARMACEUTICALS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Nadav KidronPresident, Chief Executive Officer and Chairman$4,774,460
Miriam Kidron · this pageChief Scientific Officer and director (5)$2,166,384
Joshua HexterChief Operating and Business Officer$1,882,398

The full ORAMED PHARMACEUTICALS compensation record

free company brief

This page is one person within ORAMED PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ORAMED PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ORAMED PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Miriam Kidron's compensation dossier · One-time report. No refunds.